Last reviewed · How we verify
Intravenous infusions of WCK 5222
Intravenous infusions of WCK 5222 is a Small molecule drug developed by Wockhardt. It is currently in Phase 1 development.
At a glance
| Generic name | Intravenous infusions of WCK 5222 |
|---|---|
| Sponsor | Wockhardt |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Plasma and Intrapulmonary Concentrations Study of WCK 5222 (PHASE1)
- To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment (PHASE1)
- Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers (PHASE1)
- MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous infusions of WCK 5222 CI brief — competitive landscape report
- Intravenous infusions of WCK 5222 updates RSS · CI watch RSS
- Wockhardt portfolio CI
Frequently asked questions about Intravenous infusions of WCK 5222
What is Intravenous infusions of WCK 5222?
Intravenous infusions of WCK 5222 is a Small molecule drug developed by Wockhardt.
Who makes Intravenous infusions of WCK 5222?
Intravenous infusions of WCK 5222 is developed by Wockhardt (see full Wockhardt pipeline at /company/wockhardt).
What development phase is Intravenous infusions of WCK 5222 in?
Intravenous infusions of WCK 5222 is in Phase 1.
Related
- Manufacturer: Wockhardt — full pipeline
- Compare: Intravenous infusions of WCK 5222 vs similar drugs
- Pricing: Intravenous infusions of WCK 5222 cost, discount & access